Read by QxMD icon Read

thymic carcinoma

Shizuka Kiuchi, Utano Tomaru, Akihiro Ishizu, Makoto Imagawa, Takayuki Kiuchi, Sari Iwasaki, Akira Suzuki, Noriyuki Otsuka, Takahiro Deguchi, Tomohiro Shimizu, Katsuji Marukawa, Yoshihiro Matsuno, Masanori Kasahara
Cathepsins are a group of proteolytic enzymes of the endosomal/lysosomal pathway involved in the thymic development of T cells restricted by major histocompatibility complex class II molecules. In the normal thymus, cathepsin V (CTV) and cathepsin S (CTS) are expressed in cortical and medullary epithelial cells, respectively. To investigate whether cathepsins could serve as a diagnostic marker, we performed immunohistochemical analysis for CTV and CTS in 77 cases of thymic epithelial tumors. Almost all cases (59/60) of thymoma expressed CTV, whereas 28 out of 60 cases of thymoma expressed CTS...
October 19, 2016: Human Pathology
Yalan Bi, Yinghui Deng, Shanqing Li, Xiaoyun Zhou, Yeye Chen, Dongjie Ma, Xinxin Mao, Yuzhou Guan, Jie Chen, Yunxiao Meng
OBJECTIVES: To investigate the immunoreactivity of TTF-1 and PAX8 in neuroendocrine carcinoma of thymic (TNEC) and pulmonary origins (PNEC), and whether their immunophenotyping could be used to distinguish between NEC of the two sites, as well as prognosis of patients with TNEC. METHODS: Twenty-two cases of TNEC and 20 cases of PNEC were selected for immunohistochemical analysis using PAX8 and TTF-1. Clinical data and follow-up information were obtained for survival analyses...
October 20, 2016: Journal of Surgical Oncology
Tom Wilhelm, Thomas Winkens, Almut Kunze, Martin Freesmeyer
A 65-year-old woman presented with increased human thyroglobulin (3.3 ng/mL) 5 years after resection of a papillary thyroid carcinoma and successful I radioiodine therapy. I whole-body scintigraphy showed a small focus ventrally in the right lower neck, leading to suspicion of a papillary thyroid carcinoma recurrence. I-PET/CT and real-time PET/US fusion matched to a small hypoechoic/anechoic ovoid structure situated between the right sternoclavicular joint and the brachiocephalic trunk. After surgical resection, histology allowed a diagnosis of thymic cyst...
October 5, 2016: Clinical Nuclear Medicine
Priska Leisibach, Didier Schneiter, Alex Soltermann, Yoshi Yamada, Walter Weder, Wolfgang Jungraithmayr
BACKGROUND: Thymic epithelial tumors (TET) are rare neoplasms with inconsistent treatment strategies. When researching for molecular pathways to find new therapies, the correlation between specific molecular markers and outcome has only rarely been investigated. The aim of this study was to investigate the correlation between survival, metastatic potential and invasiveness of aggressive subtypes of TET and immunohistochemical markers. METHODS: Overall survival (OS), disease-free survival (DFS), progression-free survival (PFS) and metastasis-free survival (MFS) of patients with WHO type B2/B3 mixed type thymoma (MT), thymoma type B3 (B3) and thymic carcinoma (TC), undergoing surgery [1998-2013] were determined...
September 2016: Journal of Thoracic Disease
Zu-Yang Yuan, Shu-Geng Gao, Ju-Wei Mu, Qi Xue, You-Sheng Mao, Da-Li Wang, Jun Zhao, Yu-Shun Gao, Jin-Feng Huang, Jie He
BACKGROUND: The prognostic value of serum lactate dehydrogenase (LDH) has been demonstrated in various solid tumors. We attempted to determine whether serum LDH was predictive of survival in thymic carcinoma after surgical resection. METHODS: Ninety-five patients with thymic carcinoma treated in our hospital between January 2005 and December 2015 were retrospectively enrolled. Serum LDH was measured before surgery and categorized as low or high relative to the upper limit of normal (ULN) (225 U/L)...
September 2016: Journal of Thoracic Disease
Alberto M Marchevsky, Ann E Walts
The checkpoint protein programmed cell death ligand-1 protein (PD-L1) binds to its receptor (PD-1) activating the PD-L1/PD-1 pathway, an important therapeutic target. There is limited information regarding PD-L1 and PD-1 expression in thymic lesions. Sections from non-neoplastic thymi (n=20), thymomas WHO types A, AB, B1, B2 and B3 (n=38) and thymic squamous cell carcinoma (n=8) were stained for PD-L1 (clone SP142 Spring BioScience), PD-1 (MRQ22 Cell Marque), CD4 (clone SPO32 Cell Marque) and CD8 (JCB117 Ventana)...
October 13, 2016: Human Pathology
Ping Zhan, Xiao Chen, Xiao-Yuan Wu, Zhi-Bo Hou, Qian Qian, Yu Zhang, Jue Zou, Yuan-Qing Zhang, Ming-Yue Wan, Jian-Dong Wang, Li-Ke Yu, Hai-Yan Xie
INTRODUCTION: For thymic carcinoma (TC), which is a rare epithelial neoplasm of the thymus gland, median survival with current treatments is only 2 years. OBJECTIVES: Mutations in the epidermal growth factor receptor (EGFR) gene or its downstream effectors may cause constitutive activation that leads to cell proliferation and metastases. Thus, molecular profiling is essential for selecting TC patients who may respond to anti-EGFR therapies. METHODS: Genomic DNA was extracted from 61 histological samples of TCs...
October 12, 2016: Clinical Respiratory Journal
Ms Jun Du, Qin Shen, Honglin Yin, Qiu Rao, Mr Xiaojun Zhou
MUC1 is a transmembrane mucin that has been related to tumor progression and outcome in various malignancies. GLUT1 is a member of the mammalian facilitative glucose transporter (GLUT) family of passive carriers that functions as an energy-independent system for transporting glucose. Both of them are useful markers for the diagnosis, progression, and prognosis of various tumors, especially those that are cancerous. However, the clinical significance of MUC1 and GLUT1 in thymic epithelial tumors remains uncertain due to a lack of quality specimen and studies at sufficient scale, both owing, in part, to the rarity of the tumors...
September 13, 2016: Pathology, Research and Practice
Y R Zhai, W Ji, Z Hui, X Wang, J Liang, J Lv, H Zhang, Q Feng, Z Zhou, C Dongfu, L Wang
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Geoffrey B Johnson, Marie Christine Aubry, Eunhee S Yi, Chi Wan Koo, Sarah M Jenkins, Yolanda I Garces, Randolph S Marks, Stephen D Cassivi, Anja C Roden
INTRODUCTION: Neoadjuvant treatment might increase resectability of thymic epithelial tumors (TET). No standardized pathologic grading scheme for tumor response is available. Also, it is unclear whether radiologic treatment response can predict pathologic response. METHODS: Patients with unresectable TET who underwent neoadjuvant treatment before surgery at Mayo Clinic Rochester (1942-2014) were included. The pathologic tumor response grade (TRG) was based upon Mandard-grading (1994) ranging from TRG 1 (no viable tumor) to TRG 5 (no regression)...
September 22, 2016: Journal of Thoracic Oncology
David Altree-Tacha, Jillian Tyrrell, Faqian Li
Context .- High-grade neuroendocrine carcinomas and carcinoids can arise in different sites such as lung, gastrointestinal tract, prostate, and skin. Classic neuroendocrine markers such as CD56, synaptophysin, and chromogranin cannot distinguish carcinoids from high-grade neuroendocrine carcinomas. Recently, mouse monoclonal mASH1 has been shown to help discriminate carcinoids from high-grade neuroendocrine carcinomas in various neoplastic sites. To date, there have been no comprehensive immunohistochemistry studies with mASH1 on nonneuroendocrine neoplasms...
September 15, 2016: Archives of Pathology & Laboratory Medicine
Maude Guillot-Delost, Lia Guilleré, Frédérique Berger, Aurore Ventre, Paula Michea, Philémon Sirven, Lucia Pattarini, Alix Scholer-Dahirel, Fatima-Zahra Kebir, Michel Huerre, Olfa Chouchane-Mlik, Emmanuelle Lappartient, José Rodriguez, Thomas Jouffroy, Jerzy Klijanienko, André Nicolas, Xavier Sastre-Garau, Sofia Honorio, Véronique Mosseri, Nelly Le Peltier, Marie-Paule Sablin, Christophe Le Tourneau, Éric Tartour, Cécile Badoual, Vassili Soumelis
Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-7-like cytokine expressed by epithelial cells during allergic inflammation, and activating dendritic cells (DC). Its expression and functional role in cancer remain controversial. We conducted retrospective (n = 89), and prospective studies including patients with untreated primary head and neck squamous cell carcinoma (HNSCC). We found that TSLP was overexpressed by HNSCC tumor cells, and associated with a highly differentiated status. However, no significant difference in overall and recurrence-free survival was found between patients bearing a tumor with high and low TSLP levels, respectively...
July 2016: Oncoimmunology
Tomohiro Haruki, Makoto Wakahara, Yuji Taniguchi, Yoshinobu Nakamura, Motonobu Nishimura, Hiroshige Nakamura
Although the optimal treatment strategy for locally advanced thymic carcinomas has yet to be determined, complete resection of the tumor after induction chemoradiotherapy (CRT) can sometimes provide a good chance of being cured. A 61-year-old woman was diagnosed with locally advanced primary thymic carcinoma, which invaded bilateral brachiocephalic veins and superior vena cava with intraluminal tumor thrombus. Induction CRT was performed, and a partial response to the treatment was achieved. Subsequent radical surgery was successfully performed by the median full sternotomy with a right transmanubrial osteomuscular sparing approach (TMA)...
2016: Journal of Surgical Case Reports
Nobuyasu Kurihara, Hajime Saito, Hiroshi Nanjo, Hayato Konno, Maiko Atari, Yoshitaro Saito, Satoshi Fujishima, Komei Kameyama, Yoshihiro Minamiya
INTRODUCTION: Myasthenia gravis (MG) has been reported to correlate with earlier-stage thymoma, and theoretically does not accompany thymic carcinoma. However, we encountered two cases of thymic carcinoma with MG. PRESENTATION OF CASES: Case 1 involved a 54-year-old man who had been diagnosed with MG based on symptoms and detection of anti-acetylcholine receptor antibody (ARAB). Computed tomography (CT) revealed an anterior mediastinal tumor 30mm in diameter. Prednisolone (PSL) and tacrolimus were administered without surgery at that time...
2016: International Journal of Surgery Case Reports
Keitaro Hayashi, Promsuk Jutabha, Sumiko Maeda, Yothaisong Supak, Motoshi Ouchi, Hitoshi Endou, Tomoe Fujita, Masayuki Chida, Naohiko Anzai
L-type amino acid transporter 1 (LAT1, SLC7A5) incorporates essential amino acids into cells. Recent studies have shown that LAT1 is a predominant transporter in various human cancers. However, the function of LAT1 in thymic carcinoma remains unknown. Here we demonstrate that LAT1 is a critical transporter for human thymic carcinoma cells. LAT1 was strongly expressed in human thymic carcinoma tissues. LAT1-specific inhibitor significantly suppressed leucine uptake and growth of Ty82 human thymic carcinoma cell lines, suggesting that thymic carcinoma takes advantage of LAT1 as a quality transporter and that LAT1-specific inhibitor might be clinically beneficial in therapy for thymic carcinoma...
July 27, 2016: Journal of Pharmacological Sciences
M V Bluthgen, C Boutros, F Fayard, J Remon, D Planchard, B Besse
OBJECTIVES: Standard regimens in pretreated advanced TETs are lacking. Single agent responses have been reported with pemetrexed, gemcitabine and targeted therapies. Oral etoposide monotherapy has a favorable safety and efficacy profile in other tumor types. We assessed its activity and safety in advanced or recurrent pretreated TETs. PATIENTS AND METHODS: We conducted a retrospective analysis of patients with advance or recurrent TET treated with single agent oral etoposide at Gustave Roussy (GR) between 1992 and 2015...
September 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Yuki Katsuya, Hidehito Horinouchi, Tetsuhiko Asao, Shinsuke Kitahara, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Shun-Ichi Watanabe, Koji Tsuta, Yuichiro Ohe
BACKGROUNDS: To understand the clinical impact of PD-1/L1 expression in thymoma (TM) and thymic carcinoma (TC), we evaluated the frequency of PD-1/L1 expression in pre/post chemotherapy specimens and the correlation with the treatment efficacy. METHODS: The expression of PD-1/L1 was evaluated using immunohistochemistry in patients with TM or TC treated with chemotherapy between 2000 and 2014. Using formalin-fixed, paraffin-embedded tissue samples and a PD-L1 antibody, the expression of PD-L1 in the TM and TC specimens was reported in terms of the H-score (0-300), with a score ≥1 being defined as positive...
September 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Suyon Chang, Jin Hur, Dong Jin Im, Young Joo Suh, Yoo Jin Hong, Hye-Jeong Lee, Young Jin Kim, Kyunghwa Han, Dae Joon Kim, Chang Young Lee, Ha Young Shin, Byoung Wook Choi
OBJECTIVES: To investigate the diagnostic value of dual-energy computed tomography (DECT) in differentiating between low- and high-risk thymomas and thymic carcinomas. MATERIALS: Our institutional review board approved this study, and patients provided informed consent. We prospectively enrolled 37 patients (20 males, mean age: 55.6 years) with thymic epithelial tumour. All patients underwent DECT. For quantitative analysis, two reviewers measured the following tumour parameters: CT attenuation value in contrast Hounsfield units (CHU), iodine-related HU and iodine concentration (mg/ml)...
August 23, 2016: European Radiology
Dustin Boothe, Andrew Orton, Cameron Thorpe, Kristine Kokeny, Ying J Hitchcock
INTRODUCTION: Our purpose was to determine the overall survival (OS) benefit of postoperative radiotherapy (PORT) in patients with advanced thymic malignancies and the associated predictors of PORT receipt. METHODS: We queried the National Cancer Data Base for all stage II to III thymic malignancies. Trends in PORT use over time were analyzed using least squares linear regression. Factors predictive of PORT and OS were identified by using multivariate logistic and Cox regression analysis, respectively...
August 17, 2016: Journal of Thoracic Oncology
P Ströbel, C-A Weis, A Marx
Thymic carcinomas (TC) are approximately 10 times less prevalent than thymomas but of high clinical relevance because they are more aggressive, less frequently resectable than thymomas and usually refractory to classical and targeted long-term treatment approaches. Furthermore, in children and adolescents TC are more frequent than thymomas and particularly in this age group, germ cell tumors need to be a differential diagnostic consideration. In diagnostic terms pathologists face two challenges: a), the distinction between thymic carcinomas and thymomas with a similar appearance and b), the distinction between TC and histologically similar metastases and tumor extensions from other primary tumors...
September 2016: Der Pathologe
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"